Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Braeburn/Titan Nab Powerful Ally To Push Opioid Dependence Implant

Executive Summary

With the FDA's approval in hand, the big question now is whether payers will pay for Braeburn Pharmaceuticals' and Titan Pharmaceuticals' opioid dependence implant Probuphine, whose wholesale acquisition cost has been set at $825 per month. But the companies have a strong ally on their side: Nora Volkow, head of the US National Institute of Drug Abuse, who called the product a "game-changer."

You may also be interested in...



'Norplant' Ghosts Haunt Titan/Braeburn Buprenorphine Implant

Even with new data, US regulators appeared to question whether Titan Pharmaceuticals Inc. and its partner privately held Braeburn Pharmaceuticals Inc. can safely market Probuphine, a matchstick-size subdermal implant intended to deliver buprenorphine to treat opioid dependence.

Titan plans 2nd half Probuphine resubmission on new data

With new positive Phase III results in hand, Titan Pharmaceuticals on 8 June said it will be ready by the second half of this year to resubmit its new drug application (NDA) to the FDA for Probuphine (buprenorphine hydrochloride/ethylene vinyl acetate), a subdermal implant that's under investigation as a maintenance treatment for opioid addiction.

FDA-backed study provides path forward for Probuphine

Titan Pharmaceuticals and its partner Braeburn Pharmaceuticals on 3 March said they have agreed in principle with the US FDA on the design of a trial to support the resubmission of the new drug application (NDA) for Probuphine (buprenorphine hydrochloride/ethylene vinyl acetate), a subdermal implant under investigation as a maintenance treatment of opioid dependence.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB150348

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel